Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Sen. Grassley To Be "More Insistent" About Drug Firms' Testimony At Future Hearings

“I want to express my displeasure at the lack of cooperation from the pharmaceutical manufacturers recently,” Finance Committee chair says, noting that large firms had declined invitations to speak publicly.

Pricing Debate Legislation Medicare

Latest From Pricing Debate

Health Technology Assessments And the Trouble With Rare Disease Treatments

To get their gene or cell therapies through health technology appraisals, companies need to agree to gather longer-term evidence, be upfront about what treatments can really deliver and remember to ask for patient input.

Europe Health Technology Assessment

Running The Gauntlet: Takeaways From The First Round Of HHS Hearings In 2019

Release of the White House budget proposal kicked off the first round of hearings on HHS with a new Democratic majority in the House and a new HHS budget czar in the Senate. HHS Secretary Azar did his best to set a constructive tone for advancing drug pricing policies – and maintaining his own position – in the year to come.  
Legislation Leadership

Canada Plans New Agency To Negotiate Drug Prices & Tackle Soaring Costs

A proposed new drugs agency with the power to evaluate the effectiveness of medicines and negotiate prices with manufacturers is seen as the first step towards a national pharmacare program offering universal drug coverage in Canada.
Pricing Debate Reimbursement

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

Market Access Pharmacy Benefit Management

Price ‘Anchoring’? Zolgensma And The Art Of Managing Gene Therapy Sticker Shock

Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?

Pricing Strategies Pricing Debate

Part D Premiums ‘Won’t Go Up’ With HHS Rebate Proposal, Azar Maintains

US HHS secretary tells Senate Finance Committee he believes pharmacy benefit managers will effectively keep drug costs down in Medicare Part D, even without rebates.

Medicare Reimbursement

Making The Case For Rebates: UnitedHealth Pushing Expansion Of POS Program

Faced with a proposed regulation that aims to eliminate rebates and an upcoming hearing on Capitol Hill, US pharmacy benefit managers including OptumRx are working to validate the concept of rebates when redirected to patients at the point-of-sale. 

Pharmacy Benefit Management Pricing Debate

Novartis Strikes Kymriah Outcome-Based Deal With German Insurers

Novartis and German insurers have agreed a payment by outcomes deal for its CAR-T therapy Kymriah.

Europe Germany

CREATES Act: Republican Lawmakers Worry About Frivolous Lawsuits By Generic Firms

Association for Accessible Medicines' Davis tries to counter concerns that the long-stalled measure would incentivize lawsuits against brand companies; witnesses at a House subcommittee hearing on drug pricing legislation also testified that the BLOCKING Act would create an overly broad and complicated framework for triggering 180-day exclusivity.

Pricing Debate Generic Drugs
See All
UsernamePublicRestriction

Register